| Date Filed | Type | Description |
| 08/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
8-K
| Quarterly results |
| 07/03/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 06/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/09/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/03/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/03/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/10/2023 |
SC 13G
| ARK Investment Management LLC reports a 6.4% stake in Adaptive Biotechnologies Corporation |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 8.2% stake in Adaptive Biotechnologies Corp. |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/03/2022 |
8-K
| Quarterly results |
| 09/12/2022 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 2.9% stake in ADAPTIVE BIOTECHNOLOGIES |
| 09/12/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 08/03/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/03/2022 |
8-K
| Quarterly results |
| 06/14/2022 |
8-K
| Quarterly results |
| 05/04/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/04/2022 |
8-K
| Quarterly results |
| 04/22/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/22/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/25/2022 |
8-K
| Other Events Interactive Data |
| 03/11/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/15/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 02/15/2022 |
8-K
| Quarterly results |
| 02/14/2022 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 21.3% stake in Adaptive Biotechnologies Corporation |
| 02/14/2022 |
SC 13G/A
| Matrix Capital Management Company, LP reports a 8.2% stake in Adaptive Biotechnologies Corporation |
| 02/10/2022 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 10% stake in Adaptive Biotechnologies Corp |
| 02/10/2022 |
SC 13G
| PRICE T ROWE ASSOCIATES INC reports a 9.4% stake in Adaptive Biotechnologies Corp |
| 02/09/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/10/2022 |
8-K
| Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment... |
|